169 related articles for article (PubMed ID: 37726572)
21. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Reichman K; Haslerud T; Ahmadzadehfar H; Biersack HJ; Nagarajah J; Ezziddin S
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):505-10. PubMed ID: 24196919
[TBL] [Abstract][Full Text] [Related]
22. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice.
van Angelen AA; Glaudemans B; van der Kemp AW; Hoenderop JG; Bindels RJ
Nephrol Dial Transplant; 2013 Apr; 28(4):879-89. PubMed ID: 23136218
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the efficacy of 99 mTc-DTPA scintigraphic GFR measurement with Gates method in the detection of cisplatin-induced nephrotoxicity in comparison with plasma urea and creatinine measurement.
Özülker F; Özülker T; Uzun AK; Özpaçacı T
Med Oncol; 2011 Dec; 28(4):1101-6. PubMed ID: 20467916
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
29. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
[TBL] [Abstract][Full Text] [Related]
30. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
31. Identifying cisplatin-induced kidney damage in paediatric oncology patients.
Barton CD; Pizer B; Jones C; Oni L; Pirmohamed M; Hawcutt DB
Pediatr Nephrol; 2018 Sep; 33(9):1467-1474. PubMed ID: 28821959
[TBL] [Abstract][Full Text] [Related]
32. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
[TBL] [Abstract][Full Text] [Related]
33. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R
Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group.
von der Weid NX; Erni BM; Mamie C; Wagner HP; Bianchetti MG
Nephrol Dial Transplant; 1999 Jun; 14(6):1441-4. PubMed ID: 10383005
[TBL] [Abstract][Full Text] [Related]
35. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
37. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
[TBL] [Abstract][Full Text] [Related]
38. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers JW; Chaudhry V; Cavaletti G; Donehower RC
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD005228. PubMed ID: 24687190
[TBL] [Abstract][Full Text] [Related]
39. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
40. The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis.
He L; Li J; Zhan J; Yi F; Fan X; Wei Y; Zhang W
Cancer Chemother Pharmacol; 2019 Mar; 83(3):561-571. PubMed ID: 30610366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
